NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate

NCCN has added pralatrexate (Folotyn™, Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009. October 15, 2009 FORT WASHINGTON, PA - Upon the recent FDA approval of pralatrexate (Folotyn™, Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news